# The Center for Advancing Point of Care in Heart, Lung, Blood and Sleep Diseases

> **NIH NIH U54** · UNIV OF MASSACHUSETTS MED SCH WORCESTER · 2020 · $1,570,233

## Abstract

PROJECT SUMMARY/ABSTRACT - OVERALL
American healthcare is rapidly evolving to a state where efficiency and quality in health care are
co-dominant drivers. Several emergent trends are driving fundamental changes in health care:
1) increasing numbers of patients in accountable care organizations with bundled payments to
providers; 2) emphasis on quality metrics such as reducing readmissions for heart failure and
improving control of hypertension; and 3) increasing focus on the patient as a driver of medical
decisions and a partner in care. There is now an urgent need to develop technologies that
provide rapid feedback to both caregivers and patients in order to effect timely changes in
patient self-care, symptom detection, diagnosis and treatment delivery. In particular, there is a
critical need for new evidence-based, user-friendly, patient-centric, point-of-care technologies
(POCT) to monitor health/medical status in people as they go about their daily lives out of the
clinic and to deliver actionable reports to the point of care. The Center for Advancing Point of
Care Technologies (CAPCaT) in Heart, Lung, Blood, and Sleep Diseases will be an offshoot of
a highly successful medical product incubator, the Massachusetts Medical Device Development
Center (M2D2) at the University of Massachusetts (Lowell and Worcester campuses). The
founding goal of M2D2 was to accelerate the development of medical devices, using the
combined expertise of UMass Lowell (UML) in engineering and business, and the clinical
expertise of UMass Medical School (UMMS) in Worcester. Expanding upon the vision and
success of M2D2, the goal of CAPCaT is to develop and optimize novel POCT to improve the
diagnosis and management of heart, lung, blood and sleep (HLBS) diseases. We have focused
on these diseases because of the significant morbidity, mortality, and cost associated with these
diseases. Combined, these diseases account for 41% of deaths in the US and lead to over
$400B in direct health care expenses plus lost income to affected patients and caregivers.
UMass has an established track record of clinical expertise and technology development in the
HLBS diseases. Our objectives are to: 1) identify, through stakeholder engagement, the most
promising POCTs to address unmet medical needs; 2) support developmental plans, including
pathways to adoption at the point of care; and 3) train and disseminate developing POCT to the
different stakeholders.

## Key facts

- **NIH application ID:** 9991634
- **Project number:** 5U54HL143541-03
- **Recipient organization:** UNIV OF MASSACHUSETTS MED SCH WORCESTER
- **Principal Investigator:** BRYAN O BUCHHOLZ
- **Activity code:** U54 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2020
- **Award amount:** $1,570,233
- **Award type:** 5
- **Project period:** 2018-08-22 → 2023-07-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/9991634

## Citation

> US National Institutes of Health, RePORTER application 9991634, The Center for Advancing Point of Care in Heart, Lung, Blood and Sleep Diseases (5U54HL143541-03). Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/grant/nih/9991634. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*